Biophytis - Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of
Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS
* Following this clearance, SARA-INT trial to recruit 231 patients vs. 334
* More than 80% of patients are now recruited - completion of patient
recruitment expected in Q2 2020
* Interim analysis by the study's data safety and monitoring board (DSMB)
expected in Q2 2020
Paris (France), Cambridge (Massachusetts, U.S.), February 11, 2020, 08:00 CET -
Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology
company with a primary focus on the development of its lead drug candidate,
Sarconeos (BIO101) for the treatment of neuromuscular diseases, today announces
that its protocol amendment for the SARA-INT trial, a phase 2b clinical trial
of Sarconeos (BIO101) in sarcopenia, has been cleared by the U.S. Food and Drug
Administration (FDA) and the Belgian regulatory agency, L'Agence fédérale des
médicaments et des produits de santé (AFMPS).
The protocol amendment as approved will allow reduce by 30% the number of
patients to be recruited into the SARA-INT clinical trial from 334 to 231
patients. This reduction in patient numbers will not change the objectives,
endpoints or statistical power of the SARA-INT clinical trial.
This reduction is based on a preliminary analysis of the SARA-OBS observational
study population, which experienced a faster deterioration of mobility function
as measured by the 400-meter walk test (400MWT), the primary endpoint in the
ongoing SARA-INT Phase 2b clinical trial. This finding confirmed that the more
stringent inclusion criteria in the SARA-INT trial will result in the selection
of patients that are at a high risk for mobility disability.
With a faster deterioration in mobility, it is reasonable to expect, that if
Sarconeos (BIO101) is beneficial for these patients, that a larger functional
difference will be seen between the treated patients and those who received
The amendment includes an unblinded interim analysis by the study's data safety
by the monitoring board (DSMB). The interim analysis will be based on a subset
of 50 patients that have completed six months of treatment with Sarconeos
(BIO101). The results of the interim analysis are expected in Q2 2020.
Stanislas Veillet, Chief Executive Officer of Biophytis, said, "We are very
pleased that the US and Belgium regulatory authorities have accepted our
protocol amendment to the SARA-INT clinical trial. This is an important
development as it enables us to significantly reduce the number of patients
that we need to recruit into the study without altering its objectives,
endpoints and statistical power. We now anticipate delivering topline results
towards the end of 2020."
Sam Agus, Chief Medical Officer of Biophytis, said: "Recruitment into the study
has been steadily accelerating across the trial's 20 centers in the US and 2
centers in Belgium, we are now at more than 80% of patient recruitment. As a
result, we are confident of completing recruitment in Q2 2020."
The SARA-INT study is a multicenter double-blind, placebo-controlled,
randomized interventional Phase 2b clinical trial evaluating the safety and
efficacy of Sarconeos (BIO101) administered orally in two doses (175 mg bid and
350 mg bid) in patients with sarcopenia at risk of mobility disability. The
primary endpoint is the gait-speed over the 400-meter walk test (400MWT), which
represents a measure of the participant's mobility function.
The SARA-OBS results and its impact on the SARA-INT study were presented at the
12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting
Disorders (SCWD) in Berlin (Germany) in a presentation entitled, SARA program:
Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-
INT study, on Saturday December 7, 2019.
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases.
Biophytis' lead drug candidate, Sarconeos (BIO101) is an orally administered
small molecule, which is currently in a Phase 2b clinical trial for sarcopenia
(SARA-INT) in the U.S. and Europe. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne muscular dystrophy
(DMD), for which the company was granted FDA IND approval in December 2019.
Biophytis is headquartered in Paris, France, and has offices in Cambridge,
Massachusetts. The Company's ordinary shares are listed on Euronext Growth
Paris (Ticker: ALBPS - ISIN: FR0012816825).
For more information please visit www.biophytis.com
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on Biophytis' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to securities
of Biophytis in any country. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by applicable
law, Biophytis undertakes no obligation to update or revise the information
contained in this press release. This press release has been prepared in both
French and English. In the event of any differences between the two texts, the
French language version shall prevail.